Literature DB >> 2145168

Human CD8+ intraepithelial T lymphocytes are mainly CD45RA-RB+ and show increased co-expression of CD45R0 in celiac disease.

T S Halstensen1, H Scott, P Brandtzaeg.   

Abstract

Expression of various CD45 isoforms (RA, RB and R0) on CD3+, CD4+ and CD8+ intraepithelial and lamina propria T cells was examined in situ by a three-color immunofluorescence technique in jejunal biopsy specimens from 32 patients with celiac disease and 18 controls. The median percentage of CD3+ intraepithelial lymphocytes (IEL) that expressed CD45R0 increased from 52% in controls to 69% in untreated celiac disease (p less than 0.01). Furthermore, the percentages of CD4+ and CD8+ IEL strongly positive for CD45R0 rose respectively from 94% and 24% in controls to 100% and 55% in untreated celiac disease. Conversely, CD45R0 was strongly expressed on most CD3+ lamina propria lymphocytes (LPL) both in control (81%) and diseased (77%-81%) mucosa. A variable fraction of the intraepithelial and lamina propria CD3+ T cells expressed mainly CD45RB (controls, 46% and 20%, respectively; celiac disease, 29% and 15%). Only 2% IEL and 4% LPL were positive for CD45RA. Expression of different CD45R isoforms thus identified three distinct CD8+ T cell subsets in human intestinal mucosa. In addition, our results suggested that antigen-primed CD8+CD45R0+ memory cells accumulate in the jejunal epithelium of patients with untreated celiac disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2145168     DOI: 10.1002/eji.1830200829

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  22 in total

1.  Immunoglobulin A cell distribution in the human small intestine: phenotypic and functional characteristics.

Authors:  I N Farstad; H Carlsen; H C Morton; P Brandtzaeg
Journal:  Immunology       Date:  2000-11       Impact factor: 7.397

2.  Immunohistochemical analysis of mucosal gamma-interferon production in coeliac disease.

Authors:  A al-Dawoud; I Nakshabendi; A Foulis; A M Mowat
Journal:  Gut       Date:  1992-11       Impact factor: 23.059

3.  Phenotypic heterogeneity of intraepithelial T lymphocytes from mouse small intestine.

Authors:  K J Maloy; A M Mowat; R Zamoyska; I N Crispe
Journal:  Immunology       Date:  1991-04       Impact factor: 7.397

4.  Functional properties of human lamina propria T lymphocytes assessed with mitogenic monoclonal antibodies.

Authors:  L Qiao; G Schürmann; M Betzler; S C Meuer
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

Review 5.  Mucosal T cell subsets in coeliac disease: expression of T cell receptor and CD45 isoforms.

Authors:  T S Halstensen; P Brandtzaeg
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

6.  Human intestinal intraepithelial lymphocytes, a distinct population of activated T cells.

Authors:  S Sarnacki; B Bègue; A Jarry; N Cerf-Bensussan
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

7.  Primary antigen-specific T-cell proliferative responses following presentation of soluble protein antigen by cells from the murine small intestine.

Authors:  N A Williams; A D Wilson; M Bailey; P W Bland; C R Stokes
Journal:  Immunology       Date:  1992-04       Impact factor: 7.397

8.  Selective recruitment of lymphocyte subsets to the inflamed appendix.

Authors:  K S Soo; C A Michie; S R Baker; J H Wyllie; P C Beverley
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

9.  Phenotypical characterization of peripheral blood T cells in patients with coeliac disease: elevation of antigen-primed CD45RO+ T lymphocytes.

Authors:  T O Kerttula; O Hällström; M Mäki
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

10.  Intraepithelial TcR alpha/beta+ lymphocytes express CD45RO more often than the TcR gamma/delta+ counterparts in coeliac disease.

Authors:  T S Halstensen; I N Farstad; H Scott; O Fausa; P Brandtzaeg
Journal:  Immunology       Date:  1990-12       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.